Shenzhen Mingsight Relin Pharmaceuticals Co., Ltd.

This early-stage trial tests an oral drug called MS-553 in 45 people with diabetic macular edema, a condition that causes vision loss in people with diabetes. Participants take the drug daily for 8 weeks. The main goal is to check safety, but researchers will also measure changes…